cabazitaxel
Selected indexed studies
- [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. (Lancet, 2021) [PMID:33581798]
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. (Lancet, 2010) [PMID:20888992]
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. (N Engl J Med, 2019) [PMID:31566937]
_Worker-drafted node — pending editorial review._
Connections
cabazitaxel is a side effect of
Sources
- [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. (2021) pubmed
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. (2010) pubmed
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. (2019) pubmed
- Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. (2019) pubmed
- Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. (2024) pubmed
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. (2022) pubmed
- TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. (2011) pubmed
- Current development of cabazitaxel drug delivery systems. (2023) pubmed
- Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. (2021) pubmed
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. (2017) pubmed